Cerebrolysin: Difference between revisions
Content deleted Content added
m Dating maintenance tags: {{Cn}} |
→Medical uses: tbi |
||
| Line 6: | Line 6: | ||
There is some tentative evidence of a beneficial effect on [[cognitive function]] in people with [[vascular dementia]],<ref name=":0" /> possibly through decreased [[beta-amyloid]] deposition.<ref name="MyUser_Ncbi.nlm.nih.gov_May_12_2015c">{{cite journal |title= The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders|pmid=22514792 |doi=10.1358/dot.2012.48(Suppl.A).1739716 |volume=48 Suppl A |year=2012 |journal=Drugs Today |pages=3–24 |vauthors=Masliah E, Díez-Tejedor E|doi-broken-date=31 May 2021 }}</ref> Cerebrolysin is widely used in Russia, Eastern Europe, China, and other post-Soviet and Asian countries.<ref name=":1" /> |
There is some tentative evidence of a beneficial effect on [[cognitive function]] in people with [[vascular dementia]],<ref name=":0" /> possibly through decreased [[beta-amyloid]] deposition.<ref name="MyUser_Ncbi.nlm.nih.gov_May_12_2015c">{{cite journal |title= The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders|pmid=22514792 |doi=10.1358/dot.2012.48(Suppl.A).1739716 |volume=48 Suppl A |year=2012 |journal=Drugs Today |pages=3–24 |vauthors=Masliah E, Díez-Tejedor E|doi-broken-date=31 May 2021 }}</ref> Cerebrolysin is widely used in Russia, Eastern Europe, China, and other post-Soviet and Asian countries.<ref name=":1" /> |
||
It appears to have benefit when administered following [[traumatic brain injury]].<ref>{{cite journal |last1=Ghaffarpasand |first1=F |last2=Torabi |first2=S |last3=Rasti |first3=A |last4=Niakan |first4=MH |last5=Aghabaklou |first5=S |last6=Pakzad |first6=F |last7=Beheshtian |first7=MS |last8=Tabrizi |first8=R |title=Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis. |journal=Neuropsychiatric disease and treatment |date=2019 |volume=15 |pages=127-135 |doi=10.2147/NDT.S186865 |pmid=30643411}}</ref><ref>{{cite journal |last1=El Sayed |first1=I |last2=Zaki |first2=A |last3=Fayed |first3=AM |last4=Shehata |first4=GM |last5=Abdelmonem |first5=S |title=A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury. |journal=Neurosurgical review |date=April 2018 |volume=41 |issue=2 |pages=427-438 |doi=10.1007/s10143-016-0775-y |pmid=27539610}}</ref> |
|||
==Adverse effects== |
==Adverse effects== |
||
Revision as of 19:04, 5 September 2021
 | You can help expand this article with text translated from the corresponding article in Russian. (July 2019) Click [show] for important translation instructions.
|
Cerebrolysin (developmental code name FPF-1070) is a mixture of peptides purified from pig brains that can include brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). It is alleged to have therapeutic benefit in a variety of neurological disorders.[1][2]
Medical uses
While cerebrolysin is used for stroke[3] and vascular dementia, the evidence to support this use is weak.[4] It is also sold as a nootropic.
There is some tentative evidence of a beneficial effect on cognitive function in people with vascular dementia,[4] possibly through decreased beta-amyloid deposition.[5] Cerebrolysin is widely used in Russia, Eastern Europe, China, and other post-Soviet and Asian countries.[3]
It appears to have benefit when administered following traumatic brain injury.[6][7]
Adverse effects
In trials studying post-stroke patients, the use of cerebrolysin was associated with an increased risk of serious adverse events. These were defined as:
- "any untoward medical occurrence that, at any dose, resulted in death, [was] life‐threatening, required inpatient hospitalisation or resulted in prolongation of existing hospitalisation, resulted in persistent or significant disability/incapacity, [was] a congenital anomaly/birth defect, or [was] a medically important event or reaction”.[3]
Mechanism of action
In vitro and animal studies suggest neurotrophic effects of cerebrolysin similar to endogenous neurotrophic factors, though its specific molecular pharmacodynamics are not clear.[8]
History
The preparation was allegedly first created inin 1949 by Gerhart Harrer, an Austrian professor at the University of Innsbruck.[citation needed]
Cerebrolysin has been included on the list of Vital and Essential Medicines (ЖНВЛС) in Russia since 1992.[9]
References
- ^ Windisch M, Gschanes A, Hutter-Paier B (1998). "Neurotrophic activities and therapeutic experience with a brain derived peptide preparation". J. Neural Transm. Suppl. Journal of Neural Transmission. Supplementa. 53: 289–98. doi:10.1007/978-3-7091-6467-9_25. ISBN 978-3-211-83114-4. PMID 9700665.
- ^ Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS (2012). "Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals". CNS Neurol Disord Drug Targets. 11 (1): 40–9. doi:10.2174/187152712799960781. PMID 22229324.
- ^ a b c Ziganshina, Liliya Eugenevna; Abakumova, Tatyana; Hoyle, Charles Hv (14 July 2020). "Cerebrolysin for acute ischaemic stroke". The Cochrane Database of Systematic Reviews. 7: CD007026. doi:10.1002/14651858.CD007026.pub6. ISSN 1469-493X. PMC 7387239. PMID 32662068.
- ^ a b Cui, Shuhui; Chen, Ning; Yang, Mi; Guo, Jian; Zhou, Muke; Zhu, Cairong; He, Li (11 November 2019). "Cerebrolysin for vascular dementia". The Cochrane Database of Systematic Reviews. 2019 (11). doi:10.1002/14651858.CD008900.pub3. ISSN 1469-493X. PMC 6844361. PMID 31710397.
- ^ Masliah E, Díez-Tejedor E (2012). "The pharmacology of neurotrophic treatment with Cerebrolysin: brain protection and repair to counteract pathologies of acute and chronic neurological disorders". Drugs Today. 48 Suppl A: 3–24. doi:10.1358/dot.2012.48(Suppl.A).1739716 (inactive 31 May 2021). PMID 22514792.
{{cite journal}}: CS1 maint: DOI inactive as of May 2021 (link) - ^ Ghaffarpasand, F; Torabi, S; Rasti, A; Niakan, MH; Aghabaklou, S; Pakzad, F; Beheshtian, MS; Tabrizi, R (2019). "Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: a systematic review and meta-analysis". Neuropsychiatric disease and treatment. 15: 127–135. doi:10.2147/NDT.S186865. PMID 30643411.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ El Sayed, I; Zaki, A; Fayed, AM; Shehata, GM; Abdelmonem, S (April 2018). "A meta-analysis of the effect of different neuroprotective drugs in management of patients with traumatic brain injury". Neurosurgical review. 41 (2): 427–438. doi:10.1007/s10143-016-0775-y. PMID 27539610.
- ^ Plosker, GL; Gauthier, S (2009). "Cerebrolysin: a review of its use in dementia". Drugs & aging. 26 (11): 893–915. doi:10.2165/11203320-000000000-00000. PMID 19848437.
- ^ распоряжением Правительства РФ от 7 декабря 2011 года № 2199-р
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |